NCT04732351

Brief Summary

Each new generation of phacoemulsification system has aimed to optimize the control of fluidics and the delivery of energy during phacoemulsification. Nicoli CM et al., (J Cataract Refract Surg 2016;42:157-162) suggested a better anterior chamber stability when using an active fluidics system. Malik PK et al., (Eye and Vision 2017;4:22) showed that using an IOP based phacoemulsification system in association with the use of an Intrepid balanced tip provides a reduction in CDE (Cumulated Dissipated Energy and EFU (Estimated Fluid Usage). It has also been shown that a lower CDE provides obvious benefits: less endothelium cells damages and lower complication rates (Mady MA et al., Clin.Ophthalmol. 2012; 6:503-10). The latest technologies, i.e. the Active Sentry Handpiece and Hybrid tips, have been introduced to further improve the safety of phacoemulsification. The Active Sentry system has moved pressure sensors closer to the operated eye, hence further reducing the risk of surge during procedures. (Thorne A et al. Phacoemulsifier occlusion break surge volume reduction, J Cataract Refract Surg. 2018;44:1491-1496). The Hybrid tips have been designed to prevent posterior capsule rupture in the event of contact with the capsule. This new technology allows phacoemulsification procedures under reduced infusion pressures and a "high-vacuum - low energy" strategy which may lead to a safer procedure. Data from this study will try to demonstrate that cataract surgeries with Active Sentry will need less CDE and therefore may be safer, due to the surge effects decrease. This CDE parameter will be analysed according to differents subgroups: Presence of hybrid tip or balanced tip, cataract score based on the WHO nuclear grading recommendation (Thylefors B et al., (2002) The WHO Cataract Grading Group, Ophthalmic Epidemiology, 9:2, 83-95) The recent experiences conducted in real world condition in different sites have suggested that Centurion with AS was able to improved settings: maximum vacuum and UltraSound (US) time reduction and as a consequence a 20 to 30% CDE reduction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 29, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 1, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

May 5, 2021

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2022

Completed
Last Updated

January 15, 2026

Status Verified

January 1, 2026

Enrollment Period

10 months

First QC Date

January 29, 2021

Last Update Submit

January 14, 2026

Conditions

Keywords

Cataract surgeryphacoemulsificationCumulated dissipated energyActive SentryCenturion

Outcome Measures

Primary Outcomes (1)

  • Mean CDE (Cumulated Dissipated Energy)

    Mean CDE measured by the phacoemulsifier in different groups according to baseline patients and/or eyes characteristics (nuclear cataract grading etc...)

    The day of the cataract procedure

Secondary Outcomes (5)

  • Mean total procedure duration

    The day of the cataract procedure

  • Mean total Ultrasound time (US time)

    The day of the procedure

  • Mean procedure settings

    The day of the procedure

  • Mean BSS volume

    The day of the procedure

  • Frequency of adverse events

    The day of the procedure

Study Arms (2)

Active sentry

Cataract procedures conducted with the active Sentry handpiece

Non-active sentry

Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who will undergo a cataract surgery in routine

You may qualify if:

  • All consecutive patients undergoing unilateral or bilateral cataract surgery with the Centurion phacoemulsifier, with the ability to give informed consent.
  • Patients will undergo the cataract surgery with or without the Active Sentry module and with or without hybrid tip according to centers practice.
  • Patients will undergo a cataract scoring (nuclear grade 1 to 3) prior surgery as described in the WHO recommendation:

You may not qualify if:

  • Patients with :
  • pupil dilation \<5mm
  • zonular defects
  • corneal opacities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ophtalmopôle, Hôpital Cochin

Paris, Île-de-France Region, 75014, France

Location

Related Publications (1)

  • Brezin AP, Monnet D, Lignereux F, Rozot P, Jilet L, Abdoul H. Impact of a handpiece with a built-in fluidics pressure sensor on phacoemulsification: a multicentre prospective comparative study. BMJ Open Ophthalmol. 2023 Nov;8(1):e001431. doi: 10.1136/bmjophth-2023-001431.

Study Officials

  • Antoine BREZIN, PhD & MD

    Hopital Cochin, Ophthalmology, Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 29, 2021

First Posted

February 1, 2021

Study Start

May 5, 2021

Primary Completion

March 3, 2022

Study Completion

March 3, 2022

Last Updated

January 15, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations